Emergent mutations summary
| Gene, n (%) . | Acalabrutinib, 100 mg BID (n = 47) . | Ibrutinib, 420 mg QD (n = 30) . | P value . |
|---|---|---|---|
| BTK | 31 (66.0) | 11 (36.7) | .0185 |
| By baseline cytogenetics∗ | |||
| 11q deletion | 24 (77.4) | 5 (45.5) | .0664 |
| 17p deletion | 12 (38.7) | 7 (63.6) | .18 |
| Unmutated IGHV | 28 (90.3) | 11 (100.0) | .554 |
| Complex karyotype | 18 (58.1) | 8 (72.7) | .485 |
| Trisomy 12 positive | 1 (3.2) | 2 (18.2) | .163 |
| TP53 | 6 (12.8) | 2 (6.7) | .472 |
| DNMT3A | 5 (10.6) | 1 (3.3) | .395 |
| PLCG2 | 3 (6.4) | 6 (20.0) | .142 |
| ASXL1 | 1 (2.1) | 0 | — |
| KRAS | 1 (2.1) | 0 | — |
| NRAS | 1 (2.1) | 0 | — |
| PPM1D | 1 (2.1) | 0 | — |
| RPS15 | 1 (2.1) | 0 | — |
| SAMHD1 | 1 (2.1) | 0 | — |
| TET2 | 1 (2.1) | 1 (3.3) | 1 |
| XPO1 | 1 (2.1) | 0 | — |
| FBXW7 | 0 | 1 (3.3) | — |
| NOTCH2 | 0 | 1 (3.3) | — |
| NOTCH1 | 0 | 2 (6.7) | — |
| POT1 | 0 | 1 (3.3) | — |
| Any emergent non-BTK mutation† | 14 (29.8) | 10 (33.3) | .804 |
| Any emergent mutation‡ | 36 (76.6) | 16 (53.3) | .0464 |
| Gene, n (%) . | Acalabrutinib, 100 mg BID (n = 47) . | Ibrutinib, 420 mg QD (n = 30) . | P value . |
|---|---|---|---|
| BTK | 31 (66.0) | 11 (36.7) | .0185 |
| By baseline cytogenetics∗ | |||
| 11q deletion | 24 (77.4) | 5 (45.5) | .0664 |
| 17p deletion | 12 (38.7) | 7 (63.6) | .18 |
| Unmutated IGHV | 28 (90.3) | 11 (100.0) | .554 |
| Complex karyotype | 18 (58.1) | 8 (72.7) | .485 |
| Trisomy 12 positive | 1 (3.2) | 2 (18.2) | .163 |
| TP53 | 6 (12.8) | 2 (6.7) | .472 |
| DNMT3A | 5 (10.6) | 1 (3.3) | .395 |
| PLCG2 | 3 (6.4) | 6 (20.0) | .142 |
| ASXL1 | 1 (2.1) | 0 | — |
| KRAS | 1 (2.1) | 0 | — |
| NRAS | 1 (2.1) | 0 | — |
| PPM1D | 1 (2.1) | 0 | — |
| RPS15 | 1 (2.1) | 0 | — |
| SAMHD1 | 1 (2.1) | 0 | — |
| TET2 | 1 (2.1) | 1 (3.3) | 1 |
| XPO1 | 1 (2.1) | 0 | — |
| FBXW7 | 0 | 1 (3.3) | — |
| NOTCH2 | 0 | 1 (3.3) | — |
| NOTCH1 | 0 | 2 (6.7) | — |
| POT1 | 0 | 1 (3.3) | — |
| Any emergent non-BTK mutation† | 14 (29.8) | 10 (33.3) | .804 |
| Any emergent mutation‡ | 36 (76.6) | 16 (53.3) | .0464 |
Abbreviations are explained in Table 1.
Percentages based on patients with BTK mutation.
Patients who had any newly emergent mutation during treatment in non-BTK genes (ie, a new mutation that was not present at baseline, excluding patients with BTK mutations).
Patients who had any newly emergent mutation during treatment in any gene including BTK (ie, a new mutation that was not present at baseline).